View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Clinical Trials Analysis
November 17, 2020

Global clinical trials activity increases 0.5% YoY in Q3 2020

By Carmen

Global clinical trials activity increased by 0.5% in Q3 2020, when compared with the same quarter in 2019, according to GlobalData.

Industry sponsored trials accounted for a 51.4% share of overall activity in Q3 2020, an increase of 7.5% when compared with Q3 2019.

Non-industry sponsored trials accounted for a 48.6% share of all clinical trials in Q3 2020, marking a decrease of 7.5% when compared with the same period in 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Q3 2020 industry sponsored clinical trials activity by therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2020, accounting for a 28.0% share of all trials.

This was followed by infectious disease with a 20.4% share, central nervous system with 12.8%, respiratory with 7.0% and metabolic disorders with 6.9%.

In Q3 2019, oncology led with a 29.0% share, followed by central nervous system with 14.6%, infectious disease with 11.2%, metabolic disorders with 9.0%, and cardiovascular with 8.9%.

Industry sponsored trials: Q3 2020 vs Q3 2019
Therapy Area Q3 2019 Q3 2020 Activity
Oncology 29.0% 28.0% Decrease
Infectious Disease 11.2% 20.4% Increase
Central Nervous System 14.6% 12.8% Decrease
Respiratory 5.8% 7.0% Increase
Metabolic Disorders 9.0% 6.9% Decrease
Gastrointestinal 7.9% 6.8% Decrease
Cardiovascular 8.9% 6.6% Decrease
Dermatology 5.1% 4.3% Decrease
Immunology 5.9% 4.3% Decrease
Musculoskeletal Disorders 4.3% 3.5% Decrease
Ophthalmology 3.1% 3.1% Decrease
Hematological Disorders 2.8% 2.5% Decrease
Genito Urinary System And Sex Hormones 3.1% 2.4% Decrease
Genetic Disorders 1.7% 2.1% Increase
Women’s Health 2.1% 1.5% Decrease
Ear Nose Throat Disorders 1.7% 1.1% Decrease
Male Health 0.9% 0.7% Decrease
Hormonal Disorders 0.6% 0.5% Decrease
Mouth and Dental Disorders 0.9% 0.4% Decrease
Nutritional Disorders 0.5% 0.3% Decrease
Non Malignant Disorders 0.3% 0.1% Decrease

 

Most active therapy areas in non-industry sponsored clinical trials

In Q3 2020 the leading therapy area for non-industry sponsored clinical trials was oncology, accounting for a 24.8% share of all trials.

This was followed by infectious disease with a 22.5% share, central nervous system with 20.6%, cardiovascular with 8.2%, and respiratory with 6.4%.

In Q3 2019, central nervous system held the lead in non-industry sponsored clinical trials with a 27.9% share, followed by oncology with 19.4%, cardiovascular with 8.6%, infectious disease with 8.1%, and gastrointestinal with 7.2%.

Non-Industry sponsored trials: Q3 2020 vs Q3 2019
Therapy Area Q3 2019 Q3 2020 Activity
Oncology 19.4% 24.8% Increase
Infectious Disease 8.1% 22.5% Increase
Central Nervous System 27.9% 20.6% Decrease
Cardiovascular 8.6% 8.2% Decrease
Respiratory 4.0% 6.4% Increase
Gastrointestinal 7.2% 4.9% Decrease
Metabolic Disorders 6.7% 4.4% Decrease
Women’s Health 5.4% 4.2% Decrease
Musculoskeletal Disorders 6.4% 4.0% Decrease
Hematological Disorders 3.3% 3.3% Decrease
Genito Urinary System And Sex Hormones 4.2% 3.0% Decrease
Immunology 3.7% 2.9% Decrease
Dermatology 3.9% 2.1% Decrease
Mouth and Dental Disorders 3.0% 1.8% Decrease
Ophthalmology 2.1% 1.1% Decrease
Nutritional Disorders 0.8% 0.9% Increase
Ear Nose Throat Disorders 1.6% 0.8% Decrease
Genetic Disorders 0.6% 0.7% Increase
Hormonal Disorders 0.9% 0.6% Decrease
Male Health 0.9% 0.5% Decrease
Non Malignant Disorders 0.6% 0.4% Decrease

 

Asia-Pacific region has the most activity for industry sponsored clinical trials

Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q3 2020 with a 46.2% share, compared with 52.9% in Q3 2019.

North America was the second most active region with a 38.9% share in Q3 2020, up from 31.9% in Q3 2019, followed by Europe with a 29.7% share in Q3 2020, up from 29.6% in Q3 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 82.7% share in industry sponsored clinical trials in Q3 2020, compared with 83.7% in Q3 2019. Multinational trials accounted for 17.3% in Q3 2020, against 16.3% in Q3 2019.

Regional activity for non-industry sponsored clinical trials

Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q3 2020 with a 41.2% share, down from 53.8% in Q3 2019.

North America held the second position with a 26.1% share in Q3 2020, compared with 18.4% in Q3 2019. This was followed by Middle East and Africa with a 16.1% share in Q3 2020, against 15.9% in Q3 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies accounted for 98.6% share of non-industry sponsored clinical trials in Q3 2020, compared with 98.8% in Q3 2019. Multinational trials accounted for a 1.4% share in Q3 2020, up from 1.2% in Q3 2019.

Clinical trials by phase in Q3 2020

Phase II trials outnumbered all other studies with a 37.8% share for industry sponsored trials in Q3 2020, compared with 32.5% in Q3 2019.

The share of Phase I trials stood at 33.3% in Q3 2020, down from 38.7% in Q3 2019. Phase III trials increased to 17.1% in Q3 2020, compared with 15.0% in Q3 2019, followed by Phase IV trials with an 11.8% share in Q3 2020, against 13.8% in Q3 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

For non-industry sponsored clinical trials, Phase II activity increased to a 47.2% share in Q3 2020, compared with 46.9% in Q3 2019.

Phase III trials were the second most active with a 19.3% share in Q3 2020, compared with 17.3% in Q3 2019. Phase IV trials held a 17.8% share in Q3 2020, against 19.6% in Q3 2019, followed by Phase I trials with a 15.7% share in Q3 2020, over 16.2% in Q3 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena